8-K: Sono-Tek Reports Strong Q2, Record H1 Revenue Driven by Medical

Sono-Tek Corporation announced robust second-quarter and record first-half fiscal 2026 financial results, fueled by significant growth in the medical device market.

Summary

• Second quarter fiscal 2026 net sales increased to $5.163 million, marking the sixth consecutive quarter with sales over $5 million.
• Gross profit for the second quarter increased 3% year-over-year to $2.6 million, with gross margin improving to 50%.
• Net income for the second quarter rose 24% to $424 thousand, or $0.03 per share.
• Record first half fiscal 2026 revenue increased to $10.30 million, up from $10.19 million year-over-year.
• First half gross profit increased 6% year-over-year to $5.3 million, with gross margin at 51%.
• First half net income increased 35% year-over-year to $909 thousand, or $0.06 per share.
• Cash, cash equivalents, and marketable securities totaled $10.6 million as of August 31, 2025, with no outstanding debt.
• Total equipment and service-related backlog increased 50% sequentially to $11.21 million, reflecting new order momentum from the medical market.
• Medical market sales surged 150% year-over-year in Q2 and 44% in H1, driven by balloon coating systems and stent coating activity.
• In-Line Coating Systems sales decreased 24% in Q2 due to a customer-requested delivery delay in the clean energy sector.
• Multi-Axis Coating Systems declined 41% in H1 following strong FY25 semiconductor sales and slower clean energy activity.
• US/Canada sales decreased 22% in Q2 and 5% in H1 due to slowing momentum in the US clean energy industry, offset by 153% growth in Asia in Q2 and 74% in H1.

Sentiment

Score: 8

Explanation: The company delivered strong financial performance with significant net income and gross margin improvements, record first-half revenue, and robust growth in the strategic medical market. While there are noted headwinds in clean energy and some product categories, the company's successful diversification strategy and strong backlog provide a positive outlook for continued growth and profitability.

Positives

• Achieved sixth consecutive quarter of revenue exceeding $5 million.
• Reported record first half fiscal 2026 revenue of $10.30 million.
• Net income increased significantly, up 24% in Q2 and 35% in H1.
• Gross margins improved to 50% in Q2 and 51% in H1, primarily due to favorable product mix and reduced warranty expenses.
• Medical market sales demonstrated exceptional growth, increasing 150% year-over-year in Q2 and 44% in H1.
• Backlog increased 50% sequentially to $11.21 million, indicating strong new order momentum, particularly from the medical market.
• Maintained a healthy balance sheet with $10.6 million in cash, cash equivalents, and marketable securities, and no outstanding debt.
• Successfully diversified into the medical device industry, offsetting evolving challenges in the clean energy sector.
• Management raised full fiscal year 2026 guidance slightly, anticipating modest revenue growth.

Negatives

• In-Line Coating Systems sales decreased 24% in Q2 due to a customer-requested delivery delay in the clean energy sector.
• Multi-Axis Coating Systems sales declined 41% in H1, attributed to a strong prior fiscal year for semiconductor systems not repeating and slower clean energy activity.
• The Industrial market experienced a significant decline of 68% in Q2 and 67% in H1, influenced by a large prior-year European glass coating order that did not repeat.
• US/Canada sales decreased 22% in Q2 and 5% in H1, driven by slowing momentum in the US clean energy industry.
• The Electronics market declined slightly by 1% in Q2 and more substantially by 21% in H1.
• Latin American sales decreased 45% in Q2 and 46% in H1 due to slow fluxing sales in Mexico.
• Evolving governmental clean energy incentives and tariff policies may affect the initiation and timing of customer orders.

Risks

• General economic and business conditions, including political, regulatory, tax, competitive, and technological developments, could affect operations or product demand.
• Inflationary and supply chain pressures may impact costs and profitability.
• The continued strength of sales to the medical device market is crucial for offsetting other market shifts.
• Continued private and public funding for the clean energy sector is uncertain and could impact future orders.
• Maintenance of order backlog is essential for future revenue realization.
• The imposition of tariffs could negatively affect international sales and costs.
• Timely development and market acceptance of new products and continued customer validation of coating technologies are necessary for growth.
• The ability to enforce patents is important for protecting intellectual property.
• Successful transition from primarily selling ultrasonic nozzles and components to providing complete machine solutions and higher value subsystems is a strategic challenge.
• Realization of quarterly and annual revenues within the forecasted range of sales guidance is subject to various market and operational factors.

Future Outlook

Management updated its guidance for the full fiscal year 2026, anticipating modest revenue growth. This outlook balances a cautious view regarding recent shifts in governmental clean energy and tariff policies with a positive offset from growing demand in the medical device market.

Management Comments

• Dr. Christopher L. Coccio, Executive Chairman, stated: "We are pleased to report continued growth and profitability in line with our guidance with the continuing trend of over $5 million in quarterly revenue for the past six quarters. Importantly, we remain solidly profitable with strong margins and effective cost controls. Based on projected shipments for the second half of our fiscal year 2026, we are raising guidance slightly, now anticipating modest revenue growth, taking into consideration evolving governmental clean energy incentives and tariff policies which each may affect the initiation and timing of customer orders. Despite the evolving landscape in the clean energy industry, we have successfully offset it with our diversification strategy into other sectors such as the medical device industry. It is gratifying to see the promising demand in the medical device industry that we projected coming to fruition with our recently announced $5 million dollar order for multiple state-of-the-art MediCoat systems designed for high-precision, scalable manufacturing in addition to our most recent order of over $2.8 million from another major medical device manufacturer. With a healthy balance sheet, solid backlog and strong customer demand, we remain laser focused on execution and look forward to building on our recent success."
• Steve Harshbarger, CEO & President, stated: "We continue to see the success of our growth strategies with customers moving into complex large-scale production systems with significantly higher average selling prices ASPs. Customer demand and momentum remain strong, and it is validating to see the growing adoption of Sono-Teks advanced coating platforms by leading medical device manufacturers worldwide. We are well positioned with our strong balance sheet and backlog to navigate potential short-term demand shifts that may result from changes in tariff policies and clean energy incentives. We remain focused on our long-term growth strategy and look forward to continued revenue growth and profitability over the long term."

Industry Context

The company is successfully navigating a dynamic market landscape by strategically diversifying its ultrasonic coating systems into the high-growth medical device industry. This move is effectively offsetting the impacts of evolving governmental clean energy incentives and tariff policies that are creating headwinds in the clean energy sector. This diversification positions the company to capitalize on robust demand for high-precision coating solutions in medical applications while mitigating risks in other markets.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for direct comparison.
• The company's significant growth in the medical device market (150% in Q2 and 44% in H1) suggests strong performance within this niche, especially with large orders for MediCoat systems, potentially outpacing general industry growth rates in this segment.
• The transition from R&D tools to high-volume production machines with significantly higher average selling prices indicates a strategic shift towards more mature and profitable market segments, aligning with a trend towards specialized, high-value manufacturing solutions.

Stakeholder Impact

• Shareholders are positively impacted by increased profitability, record first-half revenue, a strong balance sheet, and raised guidance, which could lead to increased shareholder value.
• Employees benefit from continued stable employment and potential growth opportunities due to the company's strong performance and strategic diversification.
• Customers, particularly in the medical device industry, benefit from advanced coating solutions and new high-precision, scalable manufacturing systems.
• Suppliers can expect continued demand for components and services due to ongoing production and a healthy backlog.

Next Steps

• Hold a conference call on October 14, 2025, to discuss the financial results.
• Continue to focus on execution and building on recent success in strategic markets.
• Pursue a long-term growth strategy leveraging innovative technologies, proprietary know-how, unique talent, experience, and global reach.
• Anticipate approximately $300k in capital expenditures for fiscal year 2026, invested in ongoing upgrades to manufacturing facilities.

Key Dates

Recommendation

The company delivered strong financial results with significant increases in net income and gross profit, alongside record first-half revenue. The strategic diversification into the high-growth medical device market is successfully offsetting challenges in the clean energy sector, as evidenced by a 150% increase in medical sales in Q2 and a 50% sequential increase in backlog. A healthy balance sheet with $10.6 million in cash and no debt provides financial stability. The raised guidance, despite market uncertainties, indicates management's confidence in continued modest revenue growth and profitability. These factors suggest a positive trajectory for the stock.

Keywords

Ultrasonic coating systems, Medical devices, Clean energy, Semiconductors, Microelectronics, Advanced industrial manufacturing, Thin film coating, SOTK, Financial results, Backlog